Posts

FDA disputes Capricor's claims of Phase 3 success for DMD cell therapy, deramiocel

on

Capricor Shares Plunge After FDA Says DMD Therapy Lacks Efficacy Ahead of Advisory Committee Meeting

on

Sarepta Taps Former AbbVie and Tessera CEO Michael Severino as New CEO to Lead Duchenne Drugmaker's Turnaround

on

Satellos Shares Early Adult Data for Duchenne Pill Ahead of Key Pediatric Readout

on

Sensorion advances hearing loss gene therapy programs

on

Servier inks up to $2.65B buyout of Edgewise's muscular dystrophy unit to boost neurology pipeline

on

Capricor Sues Nippon Shinyaku and NS Pharma Over Pricing Flaw and Launch Delays for Deramiocel DMD Therapy

on

Entrada's Stock Craters as DMD Data Underperform Expectations, Handing Advantage to Novartis

on

Roche Launches New Phase 3 Trial for Elevidys to Address EU Rejection in DMD

on

Biopharma Bites: Sarepta's Challenges with DMD Drugs Amid Full Approval Push, DMD Pipeline Advances

on

Capricor Shares Rise as FDA Sets August 2026 Decision Date for Deramiocel in Duchenne Muscular Dystrophy After Prior Rejection

on

Sarepta Therapeutics CEO Doug Ingram to Step Down by End of 2026 Amid Controversial Tenure

on

Roche Terminates Phase 2 SHIELD DMD Study for Satralizumab in Duchenne Bone Health

on

PTC Therapeutics Withdraws US NDA for Translarna in Nonsense Mutation Duchenne Muscular Dystrophy

on

Sarepta Therapeutics Reports Positive Three-Year EMBARK Data for Elevidys in Duchenne Amid Past Safety Concerns

on

The 5 Most Painful Clinical Trial Failures of 2025

on

Dyne Therapeutics Reports Positive Results for Duchenne Drug DYNE-251, Plans FDA Approval Submission

on

FDA OKs Sarepta Study of New Immune Suppression Approach with Elevidys; Gilead Acquires Preclinical TREX1 Program

on

FDA Imposes Boxed Warning and Restricts Use of Sarepta's Elevidys Gene Therapy for Duchenne Muscular Dystrophy

on

Sarepta's Duchenne Muscular Dystrophy Drugs Fail Confirmatory Trial, Company Pursues Full FDA Approval Regardless

on